377 related articles for article (PubMed ID: 19752341)
1. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
3. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
[TBL] [Abstract][Full Text] [Related]
4. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
[TBL] [Abstract][Full Text] [Related]
5. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
[TBL] [Abstract][Full Text] [Related]
6. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
Fournier A; Mesrine S; Dossus L; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N
Breast Cancer Res Treat; 2014 Jun; 145(2):535-43. PubMed ID: 24781971
[TBL] [Abstract][Full Text] [Related]
7. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
Davey DA
Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.
Yuk JS; Kim T; Cho H; Gwak G
Eur J Endocrinol; 2024 Jan; 190(1):1-11. PubMed ID: 38128117
[TBL] [Abstract][Full Text] [Related]
9. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
Beral V; Reeves G; Bull D; Green J;
J Natl Cancer Inst; 2011 Feb; 103(4):296-305. PubMed ID: 21278356
[TBL] [Abstract][Full Text] [Related]
11. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
12. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.
Reeves GK; Beral V; Green J; Gathani T; Bull D;
Lancet Oncol; 2006 Nov; 7(11):910-8. PubMed ID: 17081916
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort.
Madika AL; MacDonald CJ; Fournier A; Mounier-Vehier C; Béraud G; Boutron-Ruault MC
Menopause; 2021 Sep; 28(11):1204-1208. PubMed ID: 34581294
[TBL] [Abstract][Full Text] [Related]
15. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
17. [Menopausal hormonal therapy and cancer risks].
Lasserre A; Fournier A
Gynecol Obstet Fertil; 2016; 44(7-8):424-7. PubMed ID: 27451070
[TBL] [Abstract][Full Text] [Related]
18. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States).
Schairer C; Byrne C; Keyl PM; Brinton LA; Sturgeon SR; Hoover RN
Cancer Causes Control; 1994 Nov; 5(6):491-500. PubMed ID: 7827235
[TBL] [Abstract][Full Text] [Related]
19. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study.
Fournier A; Cairat M; Severi G; Gunter MJ; Rinaldi S; Dossus L
J Natl Cancer Inst; 2023 Jun; 115(6):671-679. PubMed ID: 36809347
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
Kerlikowske K; Cook AJ; Buist DS; Cummings SR; Vachon C; Vacek P; Miglioretti DL
J Clin Oncol; 2010 Aug; 28(24):3830-7. PubMed ID: 20644098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
